Have you seen people wandering around in public spaces, eyes glued to their smartphones, pausing and turning in different directions as if seeking some invisible landmark? Chances are you’ve spotted someone playing Pokémon GO, a location-based augmented reality game that is taking the world by storm.
Pharma Lifecycle Plagued with Integration and Data Management Challenges (Part IV – Manufacturing and Supply Chain)
In my previous blog, I discussed some of the data challenges pharmaceutical companies face during the clinical phase of drug and product development. After a drug has been approved for availability in the market, manufacturing and supply chain requirements come into focus and that phase too can be plagued with integration and data management issues.
I've got my crystal ball out. I'm peering into it with total concentration, trying to summon a vision of your organization's data-inspired future. But the glowing circle of magic dust that powers it just keeps spinning.
I think I know why. I haven't upgraded my crystal ball in a while and it doesn't have the big data processing power necessary to compute the millions (billions?) of ingenuous ways our growing data economy is sparking change—from mundane daily business operations to spectacular industry-altering discoveries.
But you don't need my crystal ball; you can create your own.
From the Q&A Files: "So with consumer sentiment—are we able to refine our product or marketing messages to arrive at a better outcome?"
This Q&A is an excerpt from our May 25, 2016 webinar: Overcoming Pharma & Healthcare Data Challenges for Competitive Advantage: Lessons from Other Industries, presented by Gary Palgon, Liaison VP of Healthcare and Life Sciences Solutions
Microsoft recently announced its $26.2 billion purchase of LinkedIn, the largest acquisition the software giant has ever made. Why is Microsoft making such a big bet on LinkedIn? Because in the data-driven economy, information is the most basic unit of value, not currency or bitcoins, and LinkedIn possesses incredibly rich data. This acquisition is further validation of the data-centric nature of today’s economy.
From the Q&A Files: "We've had Tibco for 10 years, with several hundred integration points. It’s a complex system, how can Liaison help?"
This Q&A is an excerpt from our May 26, 2016 webinar: It's Your Move: Extending the EAI/ESB, presented by Bob Renner, Liaison President and CEO
Question [Webinar participant]: We've had Tibco for 10 years, with several hundred integration points. It’s a complex system, how can Liaison help?
In my previous blog of this 6-part series, Pharma Lifecycle Plagued with Integration and Data Management Challenges (Part II – Research & Development), I discussed the impact of data integration and data management during the R&D phase. After a drug or medical device survives that stage, it enters Clinical, most often where clinical trials take place en route to becoming approved for general use.
Last month, SpaceX bullseyed a rocket landing onto a floating drone ship in the Atlantic. It's the third—and most impressive—rocket recovery by the moonshot tech company to date, bringing the reality of reusable rockets and affordable space travel one tantalizing step closer.
Mary Meeker's always-anticipated annual Internet Trends report dropped yesterday and already the tech world is abuzz with commentary and takeaways—myself included! With good reason: Meeker's insightful analysis of Internet and related technology trends provides endless talking points and an invaluable peak into the future.
I think we can all agree that the term "hybrid integration," as coined by industry analysts, is a transitional approach to the future state of systems and data integration, and not the end game. Hybrid anything (take hybrid vehicles, for example) typically represents the recognition that an emerging technology is not fully ready to stand on its own.